{"id":27345,"date":"2026-01-09T07:12:00","date_gmt":"2026-01-09T06:12:00","guid":{"rendered":"https:\/\/k2info.w.uib.no\/?p=27345"},"modified":"2026-01-09T11:17:23","modified_gmt":"2026-01-09T10:17:23","slug":"disputas-arne-carlsen-21-01-26","status":"publish","type":"post","link":"https:\/\/k2info.w.uib.no\/en\/2026\/01\/09\/disputas-arne-carlsen-21-01-26\/","title":{"rendered":"Defence \u2013 Arne Carlsen \u2013 21.01.26"},"content":{"rendered":"
\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n

FACULTY OF MEDICINE<\/strong><\/p>\n\n\n\n

UNIVERSITY OF BERGEN<\/strong><\/p>\n\n\n\n

PUBLIC DEFENCE \u2013 Ph.D. DEGREE<\/p>\n\n\n\n

Arne Carlsen<\/strong><\/p>\n\n\n\n

The candidate is affiliated with the Department of Clinical Science (Klinisk institutt 2).<\/em><\/p>\n\n\n\n

Main supervisor: Associate Professor Tore Bj\u00f8rn Grimstad
Co-supervisors: Professor Roald Omdal and Professor Conrad Bj\u00f8rshol<\/em><\/p>\n\n\n\n

Trial lecture: Wednesday, January 21, 2026 at 9:15 AM<\/strong><\/h2>\n\n\n\n

Location: Aula in Nye SUS, Ullandhaug, building C<\/p>\n\n\n\n

Given topic: \u201cEffects of dietary treatment in inflammatory bowel disease\u201d<\/p>\n\n\n\n

Debate: Wednesday 21 January 2026 at 11:00<\/strong><\/h2>\n\n\n\n

Location: Aula in Nye SUS, Ullandhaug, building C<\/p>\n\n\n\n

Title of the thesis: \"Therapeutic Drug Monitoring of Infliximab and Adalimumab in Inflammatory Bowel Disease. Impact on treatment decisions\"<\/p>\n\n\n\n

1st opponent: Professor Rasmus Goll, UiT, Arctic University of Norway<\/p>\n\n\n\n

2nd opponent: Associate Professor Ann Elisabeth \u00d8stvik, NTNU<\/p>\n\n\n\n

3rd member of the committee: Professor Conrad Bj\u00f8rshol, University of Bergen<\/p>\n\n\n\n

The defense will be led by Professor Tor K. Larsen.<\/p>\n\n\n\n

Open to all interested parties<\/p>","protected":false},"excerpt":{"rendered":"

Arne Carlsen<\/p>\n

Date: 21.january<\/p>\n

Location: Aula in Nye SUS, Ullandhaug, building C<\/p>\n

Title of the thesis: \"Therapeutic Drug Monitoring of Infliximab and Adalimumab in Inflammatory Bowel Disease. Impact on treatment decisions\"<\/p>\n

Read more →<\/a><\/p>","protected":false},"author":5375,"featured_media":27346,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[44,43439],"tags":[],"class_list":["post-27345","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nyheter","category-ph-d"],"_links":{"self":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/27345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/users\/5375"}],"replies":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/comments?post=27345"}],"version-history":[{"count":2,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/27345\/revisions"}],"predecessor-version":[{"id":27348,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/27345\/revisions\/27348"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/media\/27346"}],"wp:attachment":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/media?parent=27345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/categories?post=27345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/tags?post=27345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}